
    
      HS is a painful, chronic skin disease characterized by recurrent inflamed nodules and
      abscesses, which may rupture to form fistulas and subsequent scarring. This study is an
      open-label extension study available to subjects who participated in a prior adalimumab study
      who meet all the inclusion and none of the exclusion criteria.
    
  